⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
STOK News
Stoke Therapeutics, Inc. Common Stock
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
businesswire.com
STOK
BIIB
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
globenewswire.com
STOK
BIIB
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
globenewswire.com
STOK
BIIB
Form 8-K
sec.gov
STOK
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
businesswire.com
STOK
BIIB
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com
STOK
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
businesswire.com
STOK
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
businesswire.com
STOK
BIIB